With Tesaro off the block, will Clovis be the next PARP maker to get swallowed up?

7th December 2018 Uncategorised 0

Clovis, which markets PARP inhibitor Rubraca for ovarian cancer, has struggled to keep up with rivals like Tesaro’s Zejula and AstraZeneca and Merck’s Lynparza. That’s one of several challenges that have some biopharma experts speculating Clovis will be snapped up by an asset-hungry Big Pharma player.

More: With Tesaro off the block, will Clovis be the next PARP maker to get swallowed up?
Source: fierce